Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956809 | 1.00 | RAB9A (0.51) | RAB9ANPC1TNFNOD1MEN1 | |
| SCHEMBL21677093 | 0.87 | RAB9A (0.50) | RAB9ANPC1TNFNOD1MEN1 | |
| SCHEMBL12539143 | 0.83 | MGLL (0.41) | RAB9ANPC1TNFNOD1MEN1 | |
| SCHEMBL29951094 | 0.83 | MGLL (0.41) | RAB9ANPC1TNFNOD1MEN1 | |
| SCHEMBL21677028 | 0.83 | RAB9A (0.46) | RAB9ANPC1TNFNOD1MEN1 | |
| SCHEMBL7163455 | 0.82 | RAB9A (0.63) | RAB9ANPC1TNFNOD1MEN1 | |
| SCHEMBL2317288 | 0.81 | ALDH1A1 (0.65) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL136281 | 0.79 | ENPP2 (0.61) | KMT2AALDH1A1LMNASMN1; SMN2MAPT | |
| SCHEMBL6096 | 0.79 | ENPP2 (0.61) | MGLLALDH1A1SMN1; SMN2ENPP2KDM4E | |
| SCHEMBL5706232 | 0.78 | LPL (0.47) | ALDH1A1SMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-10-07 | — | — | US | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066308-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2025-02-27 | — | — | US | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| CN-114555588-B | Quinazoline compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-118339145-A | Bicyclic fused ring derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-07-12 | — | — | CN | disclosed |
| EP-4397655-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Yuhan Corporation (KR) | 2024-07-10 | — | — | EP | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009012375-A2 | SQUARATE KINASE INHIBITORS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| WO-2008130970-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008086158-A1 | BENZODIHYDROQUINAZOLINE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20070203218-A1 | Compounds Which Potentiate Glutamate Receptor And Uses Thereof In Medicine | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1786766-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006015829-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | RAB9A 775/4885NPC1 4021/4885TNF 4076/4885 |
| US-20250066308-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LOX, XDH, IL4I1 | RAB9A 1278/4885NPC1 737/4885TNF 3794/4885 |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | RAB9A 979/4885NPC1 2696/4885TNF 1728/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | RAB9A 979/4885NPC1 2696/4885TNF 1728/4885 |
| US-20070203218-A1 | Compounds Which Potentiate Glutamate Receptor And Uses Thereof In Medicine | GRIN1, GRM1, GLRA1 | RAB9A 899/4885NPC1 1111/4885TNF 4251/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | RAB9A 2684/4885NPC1 39/4885TNF 3424/4885 |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | RAB9A 775/4885NPC1 4021/4885TNF 4076/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | RAB9A 2101/4885NPC1 28/4885TNF 4103/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | RAB9A 979/4885NPC1 2696/4885TNF 1728/4885 |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | RAB9A 2101/4885NPC1 28/4885TNF 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.